COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #107
Source   PDF   Share   Tweet
See all 181 studies
Late treatment study
Dubernet et al., J. Global Antimicrobial Resistance, doi:10.1016/j.jgar.2020.08.001 (Peer Reviewed)
A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxych loroquine and/or corticosteroids: results of a retrospective observational study in the French overseas department of Reunion Island
Retrospective analysis of 36 hospitalized patients showing HC Q/AZ associated with lower ICU admission, p=0.008. Median age 66, no mortality. Confounding by indication, however it was patients with hypoxemic pneumonia that were treated with HC Q/AZ, patients were not treated with HC Q/AZ if they didn't need oxygen therapy.
ICU admission, ↓87.6%, p=0.008
Source   PDF   Share   Tweet
See all 181 studies
Please send us corrections, updates, or comments.